Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 242 for “"Targeted Therapies"”.
-
Targeted therapies in mantle cell lymphoma
… Rituximab is a chimeric monoclonal antibody targeted against B cells and both Rituximab-sensitive and insensitive MCL models were defined. An abnormally high expression of bcl-2, bcl-x L, mcl-1, CD40/CD40L and Fas were observed in all MCL cells, as well as high levels of soluble FasL, capable …
-
Mechanisms of artralgia in targeted therapies for cancer
Mnoho protinádorových cílených terapií má za následek neinvazivní bolesti kloubů, artralgii. Mechanismus signalizace bolesti v artralgii není zcela pochopen, ale mnoho studií vede k závěru, že zánětlivé cytokiny hrají důležitou roli v artralgii. Zvláště interleukin (IL)-6 byl detekován ve vysokých …
-
Mechanisms of medulloblastoma vulnerability and new targeted therapies
… there is an urgent need for developing new targeted therapies.The aim of this PhD research was focused on expanding the knowledge of MB biology and providing tailored therapeutic options to be used in the clinic:Project 1. A well-defined feature of MB is the genetic alterations of the cell …
-
Developing Targeted Therapies for T-cell Acute Lymphoblastic Leukemia
… common cancer in children, and risk-adapted chemotherapies have dramatically improved the outcomes of this disease. Compared to B-cell ALL, T-cell ALL (T-ALL) is more aggressive and has worse outcomes from chemotherapy. There is a great unmet need to develop biomarkers and novel targeted therapies …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… cancers, but the development of HER2-targeted therapies led to significant survival improvements. Despite this, patients often present with de novo resistance, or will develop acquired resistance to targeted therapies. Several resistance mechanisms have been identified but attempts to …
-
Mitochondrial Unfolded Protein Response Regulator Atf5 In Mitochondrial Targeted Therapies In Aml
… that AML cells are susceptible to mitochondrial targeted agents such as ONC201, an agonist of the mitochondrial protease ClpP, and gamitrinib, an inhibitor of mitochondrial chaperone TRAP1, however, these agents also induce activating transcription factor 5 (ATF5), a primary mediator of …
-
A systems approach to uncovering the adaptive response of cancer to targeted therapies
… type of mechanism to aid tumor adaptation to targeted therapies. In an effort to better probe signaling events occurring downstream of the phosphotyrosine network, a new pull down technique for mass spectrometry using 14-3-3 protein against phosphoserine and phosphothreonine peptides is …
-
The Cell Membrane Proteome of the SKBR3/HER2+ Cells and Implications for Cancer Targeted Therapies
… are highly invasive, and can be treated by using targeted therapies against the HER2 receptor. However, these therapies are challenged by the development of drug resistance, often induced by the presence of mutations in the cell-membrane proteins and receptors and/or by alternative signaling …
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… and overall survival for these patients, targeted therapies have been developed which are directed at specific pathways implicated in the proliferation of cancer cells and propogation of the tumour. One major caveat of the use of these targeted therapies is the existence of resistance, …
-
Genomics, Diagnosis, Novel Targeted Therapies and Characterisation of the Drivers of Relapse in Philadelphia Chromosome-Like Acute Lymphoblastic Leukaemia
… had significant improvements in outcomes with targeted therapies. A significant obstacle in Ph-like ALL has been imprecise case-by-case characterisation of the genomic landscape, which is especially relevant for lesions which have not yet been shown to be actionable by precision inhibitors. …
-
Integration of Genome Scale Data for Identifying New Biomarkers in Colon Cancer: Integrated Analysis of Transcriptomics and Epigenomics Data from High Throughput Technologies in Order to Identifying New Biomarkers Genes for Personalised Targeted Therapies for Patients Suffering from Colon Cancer
Colorectal cancer is the third most common cancer and the leading cause of cancer deaths in Western industrialised countries. Despite recent advances in the screening, diagnosis, and treatment of colorectal cancer, an estimated 608,000 people die every year due to colon cancer. Our current …
-
Identifying Molecular Targets and Validating Novel Therapies For Ovarian Cancer
<p>Re-purposing of targeted therapies for additional tumor types is a promising avenue for expanding treatment options for cancer patients, however accurately predicting what re-purposed targeted therapy will be effective remains challenging. To address this need, we developed a Therapy Predicting …
-
Bayesian Adaptive Clinical Trial Design
… in oncology has changed from conventional chemotherapies to molecular targeted therapies and immunotherapies, which provide innovative therapeutic modalities for treating cancers. These novel therapeutic agents work through mechanisms that fundamentally differ from standard chemotherapeutic …
-
Dual-Criterion Dose Finding Designs for Phase I Clinical Trials
… dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to targeted therapies, these traditional methods have become problematic. Many targeted therapies rarely produce DLT and are administered over multiple cycles, potentially resulting in the accumulation of …
-
Estrogen Receptor Dependent Gene Regulation in Human Breast Cancer Cells
… should assist in the development of novel targeted therapies for breast cancer prevention and treatment.
-
Investigating the Anti-Tumor Effects of Two Novel B-Catenin Inhibitors in Ovarian Cancer Cells
… is a strong candidate for the development of targeted therapies. In this study, we have identified and investigated the anti-tumor effects of two novel -catenin inhibitors, referred to as compound 2 (C2) and C10. Results from functional assays showed that C2 and C10 inhibited EOC cell …
Page 1 of 13